fbpx

Exerpts from the publication

Background
The use of ketamine for depression has increased rapidly in the past decades. Ketamine is often prescribed as add-on to other drugs used in psychiatric patients, but clear information on drug-drug interactions is lacking. With this review we aim to provide an overview of the pharmacodynamic interactions between ketamine and mood stabilizers, benzodiazepines, monoamine oxidase-inhibitors (MAOIs), antipsychotics and psychostimulants.

Methods
MEDLINE and Web of Science were searched.

Results
Twenty-four studies were included. For lithium, no significant interactions with ketamine were reported. Two out of five studies on lamotrigine indicated that the effects of ketamine were attenuated. Benzodiazepines were repeatedly shown to reduce the duration of ketamine’s antidepressant effect. For the MAO-inhibitor tranylcypromine, case reports showed no relevant changes in vital signs during concurrent S-ketamine use. One paper indicated an interaction between ketamine and haloperidol, two other studies did not. Four papers investigated risperidone, including three neuroimaging studies showing an attenuating effect of risperidone on ketamine-induced brain perfusion changes. Clozapine significantly blunted ketamine-induced positive symptoms in patients with schizophrenia, but not in healthy subjects. One paper reported no effect of olanzapine on ketamine’s acute psychotomimetic effects.

Conclusion
Current literature shows that benzodiazepines and probably lamotrigine reduce ketamine’s treatment outcome, which should be taken into account when considering ketamine treatment. There is evidence for an interaction between ketamine and clozapine, haloperidol and risperidone. Due to small sample sizes, different subject groups and various outcome parameters, the evidence is of low quality. More studies are needed to provide insight into pharmacodynamic interactions with ketamine.

Read more

Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo

Ling-Xiao Shao, Clara Liao, Ian Gregg, Pasha A. Davoudian, Neil K. Savalia, Kristina Delagarza, Alex C.Kwan
July 2021

Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission

Danilo De Gregorio, Jelena Popic, Justine P. Enns, Antonio Inserra, Agnieszka Skalecka, Athanasios Markopoulos, Luca Posa, Martha Lopez-Canul, He Qianzi, Christopher K. Lafferty, Jonathan P. Britt, Stefano Comai, Argel Aguilar-Valles, Nahum Sonenberg, and Gabriella Gobbi
February 2021

Ceremonial Ayahuasca in Amazonian Retreats—Mental Health and Epigenetic Outcomes From a Six-Month Naturalistic Study

Simon G. D. Ruffell, Nige Netzband, WaiFung Tsang, Merlin Davies, Matthew Butler, James J. H. Rucker, Luís Fernando Tófoli, Emma Louise Dempster, Allan H. Young, Celia J. A. Morgan
June 2021

Psychedelic Communitas: Intersubjective Experience During Psychedelic Group Sessions Predicts Enduring Changes in Psychological Wellbeing and Social Connectedness

H. Kettner, F. E. Rosas, C. Timmermann, L. Kärtner, R. L. Carhart-Harris, and L. Roseman
March 2021

Details